Literature DB >> 775211

Immunodeficiency in cancer and the importance of immune evaluation of the cancer patient.

E M Hersh, G M Mavligit, J U Gutterman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 775211     DOI: 10.1016/s0025-7125(16)31902-2

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


× No keyword cloud information.
  7 in total

1.  Vincristine infusion. A phase I study.

Authors:  W Weber; G A Nagel; E Nagel-Studer; R Albrecht
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Tumour markers in urology: aids in cancer diagnosis and management.

Authors:  B Wahren
Journal:  Urol Res       Date:  1979-06-22

3.  Lymphocyte transformation to phytohaemagglutinin and delayed hypersensitivity related to age and previous cancer history.

Authors:  N Sterling
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

Review 4.  Cancer immunotherapy.

Authors:  S P Richman; J U Gutterman; E M Hersh
Journal:  Can Med Assoc J       Date:  1979-02-03       Impact factor: 8.262

5.  Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes.

Authors:  C J Punt; J A Barbuto; H Zhang; W J Grimes; K D Hatch; E M Hersh
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

6.  Immunological evaluation of patients with invasive carcinoma of the gallbladder.

Authors:  L Cubillos; S González; C Sepúlveda; S Rivero; A Calvo; M Caracci; J Torres; A Tapia; J Zúñiga; C Falcón
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Stimulation of FACS-analysed CD4+ and CD8+ human tumour-infiltrating lymphocytes with ionomycin + phorbol-12,13-dibutyrate does not overcome their proliferative deficit.

Authors:  M Stoeck; S Miescher; L Qiao; P Capasso; C Barras; V von Fliedner
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.